Plain-English translation of NCT06122493 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether combining chemotherapy ( and nab-paclitaxel), an immunotherapy drug called tislelizumab, and radiation therapy can help treat advanced esophageal cancer that cannot be surgically removed. Participants receive four rounds of chemotherapy and immunotherapy first, and if their cancer doesn't grow, they then receive radiation therapy while continuing the immune-boosting medication for up to a year. The goal is to find a more effective treatment strategy for this serious condition.
Advanced esophageal cancer is difficult to treat, especially when surgery isn't an option. This trial exists to see if combining chemotherapy with a newer immunotherapy approach—which helps your own immune system fight cancer—alongside radiation might work better than standard treatments alone.
You likely qualify if…
You likely don't qualify if…
You would receive chemotherapy and immunotherapy infusions every 3 weeks for 4 cycles (about 12 weeks). After that, if your cancer hasn't progressed, you would receive daily radiation therapy (5 days a week for about 5-6 weeks) while continuing the immune-boosting medication. You would then stay on the immunotherapy alone for up to 12 months total. Throughout the trial, you'll have regular doctor visits, blood tests, and imaging scans to monitor how you're responding to treatment.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
China